摘要
目的探讨利奈唑胺对甲氧西林耐药金黄色葡萄球菌(methicillin resistant Staphylococcus aureus,MRSA)肺部感染的临床疗效及安全性。方法选取浙江省荣军医院呼吸内科诊断及治疗的甲氧西林耐药金黄色葡萄球菌肺部感染患者74例,采用随机数字表法分对照组与研究组,每组37例,对照组予以去甲万古霉素(1.0 g/次,2次/天)治疗;研究组予以利奈唑胺(600 mg/次,2次/天)治疗,共治疗2 w。治疗前后测定炎症因子及相关实验室指标,同时记录临床疗效、细菌清除率及不良反应状况。结果与治疗前比较,2组治疗后血清C反应蛋白(CRP)、白介素1β(IL-1β)、白介素6(IL-6)及肿瘤坏死因子α(TNF-α)水平降低,降钙素原(PCT)、内皮素(ET)、一氧化氮(NO)及血乳酸(Lac)水平降低(P<0.05);与对照组比较,研究组治疗后血清CRP、IL-1β、IL-6及TNF-α水平较低,PCT、ET、NO及Lac水平较低(P<0.05);在临床疗效上,对照组治疗总有效率81.08%与研究组治疗有效率91.89%对比,差异无统计学意义;在细菌清除率上,对照组总细菌清除率70.27%低于研究组的89.19%(P<0.05)。结论利奈唑胺治疗MRSA肺部感染疗效确切,降低炎症指标。
Objective To investigate the clinical effect of linezolid in the treatment of pulmonary infection with methicillin resistant Staphylococcus aureus（ MRSA）. Methods 74 cases of pulmonary infection with MRSA were selected and randomly divided into control group and study group,37 cases in each group. The control group received norvancomycin（ 1. 0 g per time,twice daily） and the study group received linezolid（ 600 mg per time,twice daily）,with a consecutive treatment of 2 weeks. The inflammatory factors and related laboratory indicators were detected,the clinical efficacy,bacterial clearance rate and adverse reaction conditions were compared after the treatment. Results Compared with before treatment,serum levels of CRP,IL-1,IL-6 and TNF-α decreased（ p〈0. 05）,levels of serum PCT,ET,NO and Lac decreased（ p〈0. 05）,compared with the control group,serum levels of CRP,IL-1,IL-6 and TNF-α in the study group were lower（ p〈0. 05）,levels of serum PCT,ET,NO and Lac were lower（ p〈0. 05）.There was no statistical difference in clinical efficacy rate between study group and control group（ 91. 89% vs. 81. 08%）,bacterial clearance rate of control group（ 70. 27%） was lower than that the study group（ 89. 19%）, and the difference was statistically significant（ p〈0. 05）.Conclusion Linezolid in the treatment of MRSA was effective with high safety,and it could reduce serum inflammation index.
出处
《中国生化药物杂志》
CAS
2016年第8期65-67,70,共4页
Chinese Journal of Biochemical Pharmaceutics
